Core Viewpoint - Bernstein Liebhard LLP has initiated a securities fraud class action lawsuit against Avantor, Inc. for alleged misrepresentations regarding the company's competitive positioning, affecting investors who purchased shares between March 5, 2024, and October 28, 2025 [3]. Group 1 - The lawsuit was filed in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who acquired Avantor common stock during the specified period [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Avantor and certain senior officers [3]. - Investors interested in serving as lead plaintiffs must file necessary documents by December 29, 2025, although participation as a class member does not require this [4]. Group 2 - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [5]. - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years, indicating a strong reputation in class action litigation [5].

Core Viewpoint - A class action securities lawsuit has been filed against Marex Group plc, alleging securities fraud that affected investors between May 16, 2024, and August 5, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Marex Group plc made false statements and concealed information regarding the improper inflation of its cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [2]. - As a result of these actions, the positive statements made by the defendants about the Company's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified time frame have until December 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against James Hardie Industries plc, alleging securities fraud that negatively impacted investors between May 20, 2025, and August 18, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that James Hardie made false statements and concealed adverse facts regarding its North America segment, including deteriorating consumer demand and growth [2]. - It is alleged that overstocking was the main driver of growth in the North America segment during the class period, rather than genuine consumer demand, leading to excessive inventory at distributors [2]. Group 2: Investor Information - Investors who suffered losses during the specified period have until December 23, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against WPP plc, alleging securities fraud that negatively impacted investors between February 27, 2025, and July 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that WPP provided overly positive statements while concealing material adverse facts about its media arm's ability to handle macroeconomic challenges and competition, leading to a loss of market share [2]. - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing this to macroeconomic uncertainty and weaker new business, compounded by distractions from ongoing restructuring [2]. - Following the trading update, WPP's stock price fell from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking an approximate decline of 18.1% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a 20-year history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - The public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Hong Kong Securities and Futures Commission (SFC) has initiated criminal proceedings against two individuals for engaging in fraudulent activities related to illegal short selling of shares in 28 Hong Kong-listed companies, violating the Securities and Futures Ordinance [1] Group 1: Legal Proceedings - The SFC has accused the defendants, Chen Haicheng and Li Baocheng, of falsely claiming that Chen held sufficient shares in the 28 companies to support sell orders issued through his account at Beigelong Securities Limited [1] - The illegal short selling occurred between May 27, 2020, and December 29, 2020, resulting in profits of approximately HKD 11 million [1] - The case has been adjourned until February 6, 2026, when the prosecution will seek to transfer the case to the District Court for further proceedings [1] Group 2: Bail Conditions - Both defendants have been granted bail pending the next hearing, with conditions including: not leaving Hong Kong, surrendering all travel documents, regular reporting to the police, posting bail of HKD 280,000 each, and residing at the declared address while notifying police of any changes [1]

Core Viewpoint - The article discusses a securities fraud class action lawsuit against DexCom, Inc. related to misleading statements and undisclosed risks associated with its G6 and G7 glucose monitoring devices, which allegedly posed health risks to users [3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, alleging that the company made unauthorized design changes to its G6 and G7 devices, compromising their reliability and safety [3]. - Allegations include that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of health risks associated with them [3]. Regulatory Issues - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management concerns, leading to a share price decline of approximately 9.15%, from $77.84 to $70.72 [4]. - The FDA's published warning on March 25, 2025, indicated that the G6 and G7 devices were "adulterated" due to unauthorized modifications, causing inaccuracies that increased health risks for users, resulting in a further share price drop of about 2.4% [5]. Market Reactions - On September 8, 2025, Oppenheimer downgraded DexCom's rating from "outperform" to "perform," citing rising concerns about the G7's accuracy and performance, which led to a share price decline of approximately 3.1% [6]. - A report by Hunterbrook Media LLC on September 18, 2025, highlighted severe health risks linked to the G7 devices, including hospitalizations and fatalities, causing a significant share price drop of about 11% [7].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. and its senior executives for securities fraud following significant stock declines attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until December 26, 2025, to request to lead the case, which is pending in the U.S. District Court for the Southern District of New York [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of DexCom investors [2]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [3]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and exposing users to health risks [4]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to quality issues with the G6 and G7, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [5]. - After the FDA published the warning letter on March 25, 2025, the stock fell an additional $3.19 per share (over 4%) [6]. - A report by Hunterbrook on September 18, 2025, revealed serious safety concerns, leading to a nearly 12% drop in stock price, equating to $8.99 per share [7].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against uniQure N.V. regarding possible violations of federal securities laws or unlawful business practices [1][3]. Group 1: Company Disclosure - On November 3, 2025, uniQure announced that the FDA no longer agrees that data from Phase I/II studies of AMT-130 may be adequate for a Biologics License Application (BLA) submission [3]. - The timing of the BLA submission for AMT-130 is now unclear following the FDA's stance [3]. Group 2: Market Reaction - Following the announcement, uniQure's share price fell by $33.40, a decline of approximately 49.33%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3].

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud, with allegations of false and misleading statements regarding its growth prospects during the fiscal year 2026 [1][5]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), and Rule 10b-5 [1]. - Investors who purchased CarMax securities between June 20, 2025, and September 24, 2025, are encouraged to participate in the lawsuit before January 2, 2026 [2]. - The lawsuit has not yet been certified, meaning potential class members are not currently represented by an attorney [4]. Group 2: Allegations Against CarMax - The complaint alleges that CarMax overstated its growth prospects, attributing early fiscal year 2026 growth to customer speculation about tariffs on vehicles [5]. - The public statements made by CarMax during the class period are claimed to be false and materially misleading, leading to investor damages once the truth was revealed [5].